In recent years, with the rapid development of tumor immunity research, immunotherapy has gradually become a promising new anticancer method, mainly represented by programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor [2, 3]. This evidence concerns the gene PDCD1 and neoplasm.